TLDR
- Pfizer posted Q1 adjusted EPS of $0.75, beating the $0.72 Wall Street estimate
- Revenue came in at $13.8 billion, with strong demand for blood thinner Eliquis
- Net earnings fell 9% year-on-year to $2.7 billion; diluted EPS dropped 10%
- Full-year 2026 guidance reaffirmed: adjusted EPS of $2.80–$3.00, revenue of $59.5B–$62.5B
- PFE stock rose around 0.5% in premarket trading to approximately $26.33
Pfizer kicked off 2026 with a Q1 earning